developmentstoday

Ask DT AI Audio Brief Videos Podcast +

Ask DT AI Audio Brief Videos Podcast

HomeHealth

Health

Health

Medical breakthroughs and health tech

Explore Related Topics

Science AI & Robotics Innovation Culture

Company

About Us
Advertise
Contact
Editorial Policy

Legal

Terms of Service
Privacy Policy
Cookie Policy
AI & Ethics Policy
Do Not Sell My Info
FAQ
Archive
Site Map

Discover

Newsletter
Ask DT AI
Audio Brief
Videos
Podcast
DT Premium

Connect

Twitter / X
Facebook
LinkedIn
YouTube
Instagram
TikTok
Flipboard
RSS Feed

© 2026 Developments Today. All rights reserved.

J&J axes pair of CAR-T therapies for lymphoma, citing evolving market

J&J Pulls Back Two Lymphoma CAR-T Programs as the Treatment Market Shifts

Johnson & Johnson is scrapping two CAR-T programs for B-cell lymphoma.
The company cites an evolving market for the decision.
The source text links the shift to recent approvals in cell therapies and antibody-based drugs for the disease.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Biotech IPO Window Reopens With Three Offerings and a Strong Debut

Endpoints says three biotech IPOs priced in the same Thursday-to-Friday window.
The combined proceeds exceeded $850 million.
The companies named are Seaport Therapeutics, Hemab Therapeutics, and Avalyn.
Avalyn rose strongly in its Nasdaq debut, suggesting renewed investor appetite.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

Amgen files update to Tavneos label as FDA escalates push to withdraw

Amgen Moves to Update Tavneos Label as FDA Pressure Intensifies

Amgen filed a supplement to add more information to Tavneos warning language.
The filing comes amid an ongoing dispute with the FDA.
The source says the FDA is escalating its push to withdraw the drug.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

Summit slips on ivonescimab

Summit Therapeutics Drops After Apparent Phase 3 Miss Revives the Market’s Biotech Patience Problem

Summit Therapeutics shares fell nearly 20% after the close on May 1, 2026.
The trigger was described as an apparent statistical miss in part of a Phase 3 trial for ivonescimab.
The move reflects how sharply biotech investors now react to ambiguous late-stage data.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

FDA approves Auvelity for Alzheimer

FDA Clears Axsome’s Auvelity for Alzheimer’s Agitation, Marking a Notable New Regulatory Step

Endpoints reports that the FDA approved Axsome Therapeutics’ Auvelity for Alzheimer’s agitation.
Axsome says up to 76% of Alzheimer’s patients experience agitation.
The supplied text characterizes agitation with symptoms including pacing and restlessness.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

FDA approves Pfizer and Arvinas

FDA clears Pfizer and Arvinas breast cancer drug, but uptake questions are already following it

The FDA approved Pfizer and Arvinas’ vepdegestrant on May 1.
The approval covers patients with a certain form of breast cancer.
Early coverage characterized the supporting data as underwhelming.
Questions about how many patients will actually use the drug are already part of the story.

DE

DT Editorial Team·May 2, 2026·via endpoints.news

More in Health→

At last, a pipeline for treating kidney disease

Kidney disease drug development is finally building a deeper bench

Nature Medicine says kidney disease is seeing a surge of targeted therapies after years of limited options.
The emerging pipeline includes immunomodulators and genetically defined drugs.
The story points to a structural shift in a field that has historically lacked new treatment depth.

DE

DT Editorial Team·May 2, 2026·via nature.com

More in Health→

FDA clears Merck’s once-daily two-drug HIV tablet for adults with suppressed virus

The FDA approved Idvynso for adults with HIV-1 who are already virologically suppressed.
The once-daily tablet combines doravirine and islatravir in a single pill.
Two randomized trials supported the approval by showing maintained viral suppression after switching.

DE

DT Editorial Team·May 2, 2026·via medicalxpress.com

More in Health→

How a Tick Bite Can Rewire What the Body Thinks Food Is

Mammalian meat allergy is described as one of the few food allergies caused by an environmental trigger.
The trigger highlighted in the source is a tick bite.
The condition results in an allergic reaction to red meat.

DE

DT Editorial Team·May 2, 2026·via medicalxpress.com

More in Health→

Digital Brain Twins Move Closer to Medicine’s Real Workflow

Researchers are building personalized computational models known as digital brain twins.
The models combine scans, activity data, and connectivity maps to simulate brain behavior.
Potential uses include predicting disease and testing treatment strategies with less direct patient risk.

DE

DT Editorial Team·May 2, 2026·via medicalxpress.com

More in Health→

Why Some Aplastic Anemia Patients Recover May Come Down to Protective Stem Cell Clones

Aplastic anemia is a rare, life-threatening disorder caused by immune attack on blood stem cells.
New research suggests protective stem cell clones may help restore marrow in some patients.
The finding could help explain why patient outcomes differ and how recovery occurs.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

Researchers Trace Ketamine’s Fast Antidepressant Effects to a Specific Brain Circuit

Researchers published the study in Cell.
The work links ketamine’s effects to specific opioid receptors on prefrontal cortex interneurons.
The finding may support development of rapid-acting antidepressants with fewer side effects.
Ketamine remains clinically useful but limited by short-lived effects and safety concerns.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

UK data points to sharper maternity risks for pregnant migrants

Medical Xpress highlighted elevated emergency cesarean risk among pregnant migrants in the UK.
The supplied text also pointed to severe maternal complications requiring ICU care or transfusion.
Infant health outcomes in poor circumstances were also described as substantially worse.
The figures reinforce concerns about structural barriers in maternity care.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

Patients Tell Medical AI Less Than They Tell Doctors, Study Warns

Participants gave less detailed symptom reports when they believed AI would read them.
The study tested simulated reports for headaches and flu-like symptoms.
Researchers say weaker disclosure could reduce digital triage accuracy and safety.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

Why Ultra-Processed Foods Keep Winning the Attention Battle

Medical Xpress highlights continued global growth in ultra-processed food consumption.
The report frames the problem around design and marketing that encourage craving.
The story points to a structural public-health challenge rather than a simple consumer-choice issue.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

GLP-1 Heart Benefits Hold Up in Long-Term Review

A long-term review of 11 trials linked GLP-1 drugs to lower rates of heart attack, stroke, and cardiovascular death.
The analysis covered more than 90,000 patients and focused only on studies with at least one year of follow-up.
Benefits were reported in high-risk patients with obesity, type 2 diabetes, or existing heart disease.
Serious safety concerns were not meaningfully increased versus placebo, though gastrointestinal side effects remained common.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

Study Points to Birth Weight as a Possible Early Marker of Human Endurance Limits

Researchers are examining whether birth weight may be linked to endurance limits seen in punishing races.
The study raises the possibility that part of long-duration physical capacity is shaped very early in development.
Any relationship would add to, not replace, known influences such as training, health, and environment.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

U.S. Measles Elimination Status Comes Under Pressure as Outbreaks Reach 45 States

A Lancet analysis says the U.S. has missed four of the CDC’s seven measles-elimination indicators.
Researchers report outbreaks that began in Texas in January 2025 have spread to 45 states.
Most recent cases were linked to domestic transmission rather than importations from abroad.

DE

DT Editorial Team·May 1, 2026·via medicalxpress.com

More in Health→

Nature Medicine study points to a more granular way to measure obesity risk

The study says future risk for 18 obesity-related diseases can be predicted using 20 common health measures.
The source frames the finding around people with the same weight facing very different medical futures.
The research was published in Nature Medicine, suggesting a clinically significant attempt at earlier risk detection.

DE

DT Editorial Team·Apr 30, 2026·via medicalxpress.com

More in Health→

Researchers found a new way to strip drug-resistant tumors of a key DNA repair advantage

Researchers identified UNI418 as a molecule that reduces key DNA repair proteins in cancer cells.
The compound appears to work by activating the Cul4A ubiquitin ligase degradation pathway.
The finding could point to a new strategy for overcoming resistance to DNA-damage-based cancer therapies.

DE

DT Editorial Team·Apr 30, 2026·via medicalxpress.com

More in Health→

……